Email address,Domain name,Organization,Country,State,City,Postal code,Street,Confidence score,Type,Number of sources,Pattern,First name,Last name,Department,Position,Twitter handle,LinkedIn URL,Phone number,Source 1,Source 2,Source 3,Source 4,Source 5,Source 6,Source 7,Source 8,Source 9,Source 10,Source 11,Source 12,Source 13,Source 14,Source 15,Source 16,Source 17,Source 18,Source 19,Source 20,Source 21,Source 22,Source 23,Source 24,Source 25,Source 26,Source 27,Source 28,Source 29,Source 30
george.wan@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,2,{first}.{last},George,Wan,,,,,,http://drugsincontext.com/wp-content/uploads/2021/01/dic-2020-9-4.pdf,http://drugsincontext.com/wp-content/uploads/2022/03/dic.2021-10-4.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,
sophie.earls@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,3,{first}.{last},Sophie,Earls,,,,,,http://therakos.fr/media/a24f3crg/mp-5124-london-gvhd-landscape-flyer-v4a.pdf,http://therakos.fr/media/rjrllc1i/tks-london-pan-1-agenda-23.pdf,http://therakos.eu/media/ugbnepsy/mp-5124-london-gvhd-landscape-flyer-v4a.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,
scott.collier@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,6,{first}.{last},Scott,Collier,,,,,,http://mallinckrodt.com/globalassets/documents/corporate/mnk---monitor-report-2.pdf,http://dmpmandyou.com/globalassets/documents/corporate/mnk---monitor-report-2.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/mnk---monitor-report-2.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/mnk---monitor-report-2.pdf,http://mp-brand.com/globalassets/documents/corporate/mnk---monitor-report-2.pdf,http://mp-branding.com/globalassets/documents/corporate/mnk---monitor-report-2.pdf,,,,,,,,,,,,,,,,,,,,,,,
molly.smith@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,1,{first}.{last},Molly,Smith,,"","","",+1 682 552 6149,http://smallpawsrescue.org/location/molly-smith,,,,,,,,,,,,,,,,,,,,,,,,,,,,
kevin.lin@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,1,{first}.{last},Kevin,Lin,,"","",https://www.linkedin.com/company/aurinia-pharmaceuticals/,"",http://vsronline.org/2022-exhibit-directory,,,,,,,,,,,,,,,,,,,,,,,,,,,,
brian.blankenship@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,1,{first}.{last},Brian,Blankenship,,"","","","",http://surgicaleyecarefoundation.net/mallinckrodt-pharmaceuticals,,,,,,,,,,,,,,,,,,,,,,,,,,,,
karin.wilkenson@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,3,{first}.{last},Karin,Wilkenson,,"","","","",http://therakos.fr/media/nl2jlxqb/cardiorenal-meeting.pdf,http://therakos.eu/media/2gjlxx2h/cardiorenal-meeting.pdf,http://theupperroom.co.uk/therakos/copenhagen/photopheresis-agenda.html,,,,,,,,,,,,,,,,,,,,,,,,,,
hermann.schultze@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,2,{first}.{last},Hermann,Schultze,,,,,,http://ema.europa.eu/medicines/human/orphan-designations/eu311945,http://ema.europa.eu/en/medicines/human/orphan-designations/eu3182054,,,,,,,,,,,,,,,,,,,,,,,,,,,
rhonda.sciarra@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,12,{first}.{last},Rhonda,Sciarra,Writing & communication,Senior Communications Manager,aofafinance,"",+1 908 238 6765,http://prnewswire.co.uk/news-releases/mallinckrodt-announces-donation-of-two-transport-vehicles-to-coolmine-therapeutic-community-tc-693503211.html,http://article-market.com/health-en/mallinckrodt-announces-donation-of-two-transport-vehicles-to-coolmine-therapeutic-community-tc-2,http://coromell.net/en/health-en/mallinckrodt-announces-donation-of-two-transport-vehicles-to-coolmine-therapeutic-community-tc,http://coromell.net/en/health-en/mallinckrodt-announces-donation-of-two-transport-vehicles-to-coolmine-therapeutic-community-tc-2,http://biospace.com/article/releases/new-health-economic-data-on-mallinckrodt-s-ofirmev-acetaminophen-injection-published-in-journal-of-knee-surgery,http://biospace.com/article/u-s-fda-announces-joint-advisory-committee-review-of-mallinckrodt-s-abuse-deterrent-immediate-release-reformulation-of-roxicodone-oxycodone-hydrochloride-,http://tass.com/press-releases/995145,http://benzinga.com/pressreleases/18/08/r12242476/mallinckrodt-confirms-receipt-of-stannsoporfin-complete-response-lette,http://prnewswire.com/news-releases/mallinckrodt-presents-terlipressin-clinical-data-at-the-liver-meeting-2018-300747446.html,http://biospace.com/article/releases/mallinckrodt-plans-spin-off-of-specialty-generics-business-to-shareholders,http://ufirms.ru/news/world/mallinckrodt-announces-first-investigator-award-for-pioneering-efforts-in-ecp-immunomodulation.html,http://business-post.ru/mallinckrodt-announces-first-investigator-award-for-pioneering-efforts-in-ecp-immunomodulation,,,,,,,,,,,,,,,,,
daniel.speciale@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",94,personal,30,{first}.{last},Daniel,Speciale,,,,,,http://financialreports.eu/news/releases/20230823en90554,http://lelezard.com/communique-19024811.html,http://pharmasalmanac.com/articles/mallinckrodt-updates-plans-for-company-separation-and-spin-off-of-specialty-generics-business-to-shareholders,http://oncologytube.com/article/39768/mallinckrodt-receives-approval-in-japan-of-the-cellex%c2%ae-extracorporeal-photopheresis-system-for-treatment-of-chronic-graft-versus-host-disease,http://ufirms.ru/news/world/mallinckrodt-announces-first-investigator-award-for-pioneering-efforts-in-ecp-immunomodulation.html,http://northdakotadigitalnews.com/2023/01/22/2023-01-22-nyseammnk-press-release,http://oncologytube.com/channel/cancer-news,http://gateo.de/mallinckrodt-kundigt-fur-das-jahr-2020-auszeichnung-zur-unterstutzung-der-ecp-immunmodulationsforschung-an-1766309.html,http://biospace.com/article/releases/mallinckrodt-completes-expansion-of-operations-and-manufacturing-facility-for-stratagraft-regenerative-skin-tissue-in-madison-wis-,http://epicos.com/article/562165/mallinckrodt-and-novoteris-receive-clearance-health-canada-start-pilot-trial-high,http://simdoms.xyz/mallinckrodt-supports-healthcare-businesswomens-affiliation-as-two-workforce-honored-with-notable-awards.html,http://europapress.es/comunicados/internacional-00907/noticia-comunicado-mallinckrodt-estudia-eficacia-inmunomodulacion-fec-pacientes-trasplante-pulmon-sbo-20190405212134.html,http://biospace.com/article/releases/mallinckrodt-emerges-from-chapter-11-with-strengthened-balance-sheet-and-enhanced-financial-flexibility,http://epicos.com/article/548572/mallinckrodt-present-new-data-two-studies-actharr-gel-repository-corticotropin,http://minnesotadigitalnews.com/2022/10/24/mallinckrodt-receives-approval-to-list-on-nyse-american,http://koreabizwire.com/silence-therapeutics-and-mallinckrodt-announce-collaboration-to-develop-and-commercialize-rnai-therapeutics-for-complement-mediated-diseases/140944,http://notimerica.com/comunicados/noticia-comunicado-mallinckrodt-anuncia-lanzamiento-premio-2020-apoyo-avance-inmunomodulacion-fec-20191030080237.html,http://tass.com/press-releases/995145,http://biospace.com/article/releases/new-health-economic-data-on-mallinckrodt-s-ofirmev-acetaminophen-injection-published-in-journal-of-knee-surgery,http://cardiacvascularnews.com/mallinckrodt-announces-publication-of-real-world-data-on-the-use-of-extracorporeal-photopheresis-ecp-in-heart-transplant-patients,http://centralcharts.com/en/16536-mallinckrodt-plc/news/2236284-mallinckrodt-announces-publication-of-results-of-phase-1b-clinical-trial-of-stratagraft-regenerative-tissue-in-burns,http://cardiacvascularnews.com/mallinckrodt-announces-submission-of-510k-to-the-u-s-fda-for-inhaled-nitric-oxide-delivery-system,http://medef.ru/blog/655,http://coromell.net/en/health-en/mallinckrodt-announces-donation-of-two-transport-vehicles-to-coolmine-therapeutic-community-tc-2,http://coromell.net/en/health-en/mallinckrodt-announces-donation-of-two-transport-vehicles-to-coolmine-therapeutic-community-tc,http://pharmiweb.com/press-release/2020-06-01/mallinckrodt-will-appeal-district-court-ruling-in-case-involving-ongoing-acthar-medicaid-drug-rebate,http://jp.prnasia.com/story/54942-3.shtml,http://jp.prnasia.com/story/90525-3.shtml,http://pharmiweb.com/press-release/2020-02-27/mallinckrodt-to-present-new-data-from-two-studies-on-acthar-gel-repository-corticotropin-injection-1,http://studyscavenger.com/mallinckrodt-announces-positive-top-line-results-from-its-pivotal-phase-3-confirm-trial-of-terlipressin-in-patients-with-hepatorenal-syndrome-type-1-hrs-1
kimberley.mandrell@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",93,personal,5,{first}.{last},Kimberley,Mandrell,,,,,,http://epsilonsigmaalpha.org/episilonsigmaalpha/media/esa_foundation/about/esa%20foundation/nomination-form-05-15-2023.pdf,http://epsilonsigmaalpha.org/episilonsigmaalpha/media/esa_foundation/scholarships%20and%20grants/esa%20foundation/esa%20foundation%20newsletters/esaf-fall-newsletter.pdf,http://epsilonsigmaalpha.org/episilonsigmaalpha/media/esa_foundation/scholarships%20and%20grants/esa%20foundation/esa%20foundation%20newsletters/esaf-spring-newsletter.pdf,http://epsilonsigmaalpha.org/episilonsigmaalpha/media/esa_foundation/scholarships%20and%20grants/esa%20foundation/esa%20foundation%20newsletters/esaf-winter-newsletter.pdf,http://epsilonsigmaalpha.org/episilonsigmaalpha/media/esa_foundation/scholarships%20and%20grants/esa%20foundation/esa%20foundation%20newsletters/summer-2023-issue.pdf,,,,,,,,,,,,,,,,,,,,,,,,
andrea.ferrero@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",93,personal,6,{first}.{last},Andrea,Ferrero,,,,,,http://therakos.fr/media/0n0l42p5/clad-and-ecp_strasbourg.pdf,http://therakos.fr/media/sjabgeaq/clad-and-ecp_nantes.pdf,http://therakos.fr/media/so4gbi2x/clad-and-ecp_lyon.pdf,http://therakos.eu/media/capdrlu5/clad-and-ecp_nantes.pdf,http://therakos.eu/media/ij5nh01o/clad-and-ecp_strasbourg.pdf,http://therakos.eu/media/nobfj0on/clad-and-ecp_lyon.pdf,,,,,,,,,,,,,,,,,,,,,,,
derek.belz@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",93,personal,9,{first}.{last},Derek,Belz,Finance,Vice President Investor Relations,"","","",http://financialreports.eu/news/releases/20230823en90554,http://cardiacvascularnews.com/mallinckrodt-announces-publication-of-real-world-data-on-the-use-of-extracorporeal-photopheresis-ecp-in-heart-transplant-patients,http://prnewswire.com/es/comunicados-de-prensa/mallinckrodt-anuncia-datos-sobre-el-uso-de-fotoferesis-extracorporea-en-pacientes-con-trasplante-de-corazon-301849546.html,http://northdakotadigitalnews.com/2023/01/22/2023-01-22-nyseammnk-press-release,http://biospace.com/article/releases/mallinckrodt-announces-anticipated-chapter-11-emergence-and-provides-update-on-trading-of-new-ordinary-shares,http://biospace.com/article/releases/mallinckrodt-emerges-from-chapter-11-with-strengthened-balance-sheet-and-enhanced-financial-flexibility,http://cardiacvascularnews.com/mallinckrodt-announces-submission-of-510k-to-the-u-s-fda-for-inhaled-nitric-oxide-delivery-system,http://24worldmedia.com/newsroom/mallinckrodt-to-report-earnings-results-for-third-quarter-2022,http://minnesotadigitalnews.com/2022/10/24/mallinckrodt-receives-approval-to-list-on-nyse-american,,,,,,,,,,,,,,,,,,,,
andrew.anguiano@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",93,personal,1,{first}.{last},Andrew,Anguiano,,"","","","",http://vsronline.org/2022-exhibit-directory,,,,,,,,,,,,,,,,,,,,,,,,,,,,
tracy.gange@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",93,personal,1,{first}.{last},Tracy,Gange,,"","","","",http://vsronline.org/2022-exhibit-directory,,,,,,,,,,,,,,,,,,,,,,,,,,,,
joseph.grieco@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",93,personal,3,{first}.{last},Joseph,Grieco,Medical & health,Director Of Clinical Development,"","","",http://ophthalmologytimes.com/view/repository-corticotropin-injections-relief-refractory-severe-noninfectious-keratitis,http://hhmr.org/post/current-research-on-uveitis,http://europe.ophthalmologytimes.com/view/injections-offer-relief-refractory-severe-noninfectious-keratitis,,,,,,,,,,,,,,,,,,,,,,,,,,
lavinia.pascucci@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",93,personal,1,{first}.{last},Lavinia,Pascucci,,Process Specialist,"","",+39 342 858 7575,http://theupperroom.co.uk/therakos/hamburg/hamburg-2018.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
mark.tyndall@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",93,personal,11,{first}.{last},Mark,Tyndall,Executive,Senior Vice President,"","",+1 202 383 0090,http://biospace.com/article/releases/mallinckrodt-announces-anticipated-chapter-11-emergence-and-provides-update-on-trading-of-new-ordinary-shares,http://biospace.com/article/releases/mallinckrodt-emerges-from-chapter-11-with-strengthened-balance-sheet-and-enhanced-financial-flexibility,http://markets.businessinsider.com/news/stocks/mallinckrodt-announces-u-s-fda-approval-of-stratagraft-allogeneic-cultured-keratinocytes-and-dermal-fibroblasts-in-murine-collagen-dsat-1030526068,http://pharmiweb.com/press-release/2020-06-01/mallinckrodt-will-appeal-district-court-ruling-in-case-involving-ongoing-acthar-medicaid-drug-rebate,http://benzinga.com/pressreleases/20/04/n15715122/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-high-dose-,http://epicos.com/article/562165/mallinckrodt-and-novoteris-receive-clearance-health-canada-start-pilot-trial-high,http://pharmasalmanac.com/articles/mallinckrodt-updates-plans-for-company-separation-and-spin-off-of-specialty-generics-business-to-shareholders,http://biospace.com/article/releases/mallinckrodt-completes-expansion-of-operations-and-manufacturing-facility-for-stratagraft-regenerative-skin-tissue-in-madison-wis-,http://biospace.com/article/mallinckrodt-plans-spin-off-of-specialty-generics-business-to-shareholders,http://prnewswire.com/news-releases/mallinckrodt-plans-spin-off-of-specialty-generics-business-to-shareholders-300761097.html,http://biospace.com/article/releases/mallinckrodt-plans-spin-off-of-specialty-generics-business-to-shareholders,,,,,,,,,,,,,,,,,,
meredith.fischer@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",93,personal,12,{first}.{last},Meredith,Fischer,Writing & communication,Chief Public Affairs,aofafinance,"",+1 314 654 3318,http://prnewswire.co.uk/news-releases/mallinckrodt-announces-donation-of-two-transport-vehicles-to-coolmine-therapeutic-community-tc-693503211.html,http://medef.ru/blog/655,http://coromell.net/en/health-en/mallinckrodt-announces-donation-of-two-transport-vehicles-to-coolmine-therapeutic-community-tc,http://coromell.net/en/health-en/mallinckrodt-announces-donation-of-two-transport-vehicles-to-coolmine-therapeutic-community-tc-2,http://biospace.com/article/releases/new-health-economic-data-on-mallinckrodt-s-ofirmev-acetaminophen-injection-published-in-journal-of-knee-surgery,http://biospace.com/article/u-s-fda-announces-joint-advisory-committee-review-of-mallinckrodt-s-abuse-deterrent-immediate-release-reformulation-of-roxicodone-oxycodone-hydrochloride-,http://tass.com/press-releases/995145,http://benzinga.com/pressreleases/18/08/r12242476/mallinckrodt-confirms-receipt-of-stannsoporfin-complete-response-lette,http://prnewswire.com/news-releases/mallinckrodt-presents-terlipressin-clinical-data-at-the-liver-meeting-2018-300747446.html,http://biospace.com/article/releases/mallinckrodt-plans-spin-off-of-specialty-generics-business-to-shareholders,http://ufirms.ru/news/world/mallinckrodt-announces-first-investigator-award-for-pioneering-efforts-in-ecp-immunomodulation.html,http://business-post.ru/mallinckrodt-announces-first-investigator-award-for-pioneering-efforts-in-ecp-immunomodulation,,,,,,,,,,,,,,,,,
critcare-info@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",92,generic,16,{first}.{last},,,Support,,,,,http://mallinckrodt.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mp-branding.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mp-branding.com/products/brands/brands-contact,http://mallinckrodt.com/products/brands/brands-contact,http://dmpmandyou.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://dmpmandyou.com/products/brands/brands-contact,http://mallinckrodtbrand.com/products/brands/brands-contact,http://stopinfantilespasm.com/products/brands/brands-contact,http://stopinfantilespasms.org/products/brands/brands-contact,http://mallinckrodtbranding.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://stopinfantilespasm.org/products/brands/brands-contact,http://stopinfantilespasm.net/products/brands/brands-contact,http://mallinckrodtbranding.com/products/brands/brands-contact,http://stopis.org/products/brands/brands-contact,http://inomax.com/contact-us/international-contacts,,,,,,,,,,,,,
dpharma@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",92,personal,14,{first}.{last},,,,,,,,http://mallinckrodt.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://dmpmandyou.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://mallinckrodtbranding.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://mp-branding.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://dmpmandyou.com/products/generics/generics-contact,http://stopinfantilespasm.org/products/generics/generics-contact,http://mallinckrodt.com/products/generics/generics-contact,http://mp-branding.com/products/generics/generics-contact,http://stopinfantilespasms.org/products/generics/generics-contact,http://stopinfantilespasm.com/products/generics/generics-contact,http://stopinfantilespasm.net/products/generics/generics-contact,http://stopis.org/products/generics/generics-contact,http://mallinckrodtbranding.com/products/generics/generics-contact,http://mp-brand.com/products/generics/generics-contact,,,,,,,,,,,,,,,
pmquality@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",92,generic,30,{first}.{last},,,,,,,,http://mallinckrodt.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mallinckrodt.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mallinckrodt.com/products/generics/resource-tool-kit/generics-faq,http://mp-branding.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mp-branding.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mp-branding.com/products/brands/brands-contact,http://mp-branding.com/products/generics/resource-tool-kit/generics-faq,http://mallinckrodt.com/products/brands/brands-contact,http://mallinckrodt.com/products/generics/generics-contact,http://dmpmandyou.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://dmpmandyou.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mallinckrodtbranding.com/products/generics/resource-tool-kit/generics-faq,http://stopinfantilespasm.org/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mallinckrodtbrand.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://dmpmandyou.com/products/brands/brands-contact,http://dmpmandyou.com/products/generics/generics-contact,http://dmpmandyou.com/products/generics/resource-tool-kit/generics-faq,http://stopinfantilespasm.org/products/brands/brands-contact,http://stopinfantilespasm.org/products/generics/generics-contact,http://mallinckrodtbranding.com/products/brands/brands-contact,http://mallinckrodtbrand.com/products/brands/brands-contact,http://stopinfantilespasm.com/products/brands/brands-contact,http://stopinfantilespasms.org/products/brands/brands-contact,http://mp-branding.com/products/generics/generics-contact,http://stopinfantilespasms.org/products/generics/generics-contact,http://stopinfantilespasm.com/products/generics/generics-contact,http://mallinckrodtbranding.com/products/generics/generics-contact
supplier.support@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",92,generic,18,{first}.{last},,,Support,,,,,http://mallinckrodt.com/globalassets/documents/corporate/mallinckrodt-supplier-code-of-conduct.pdf,http://dmpmandyou.com/globalassets/documents/corporate/mallinckrodt-supplier-code-of-conduct.pdf,http://stopinfantilespasms.org/globalassets/documents/corporate/mallinckrodt-supplier-code-of-conduct.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/mallinckrodt-supplier-code-of-conduct.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/mallinckrodt-supplier-code-of-conduct.pdf,http://mallinckrodtbrand.com/globalassets/documents/corporate/mallinckrodt-supplier-code-of-conduct.pdf,http://mp-brand.com/globalassets/documents/corporate/mallinckrodt-supplier-code-of-conduct.pdf,http://mp-branding.com/globalassets/documents/corporate/mallinckrodt-supplier-code-of-conduct.pdf,http://dmpmandyou.com/about/partnering/suppliers/diversity,http://stopinfantilespasm.org/about/partnering/suppliers/diversity,http://stopinfantilespasms.org/about/partnering/suppliers/diversity,http://stopinfantilespasm.com/about/partnering/suppliers/diversity,http://stopinfantilespasm.net/about/partnering/suppliers/diversity,http://mp-branding.com/about/partnering/suppliers/diversity,http://mallinckrodtbrand.com/about/partnering/suppliers/diversity,http://mp-brand.com/about/partnering/suppliers/diversity,http://mallinckrodt.com/about/partnering/suppliers/diversity,http://mallinckrodtbranding.com/about/partnering/suppliers/diversity,,,,,,,,,,,
edgrants@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",92,personal,11,{first}.{last},,,,,,,,http://dmpmandyou.com/research/medical-affairs/research-educational-grants/independent-medical-education,http://stopinfantilespasm.org/research/medical-affairs/research-educational-grants/independent-medical-education,http://stopinfantilespasms.org/research/medical-affairs/research-educational-grants/independent-medical-education,http://stopinfantilespasm.com/research/medical-affairs/research-educational-grants/independent-medical-education,http://stopinfantilespasm.net/research/medical-affairs/research-educational-grants/independent-medical-education,http://mp-branding.com/research/medical-affairs/research-educational-grants/independent-medical-education,http://mallinckrodtbrand.com/research/medical-affairs/research-educational-grants/independent-medical-education,http://mp-brand.com/research/medical-affairs/research-educational-grants/independent-medical-education,http://mallinckrodt.com/research/medical-affairs/research-educational-grants/independent-medical-education,http://mallinckrodtbranding.com/research/medical-affairs/research-educational-grants/independent-medical-education,http://mallinckrodt.versaic.com/message/profile_inactive,,,,,,,,,,,,,,,,,,
investor.relations@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",92,generic,30,{first}.{last},,,Writing & communication,,,,,http://bamagazine.com/en/stocks/nyse/buy-mallinckrodt-stocks-nyse-mnk,http://mallinckrodt.com/investors/annual-reports,http://mallinckrodt.com/investors/events-calendar,http://mallinckrodt.com/investors,http://mallinckrodt.com/investors/supplemental-financial-information,http://mp-brand.com/contact-us,http://mp-branding.com/investors,http://mp-branding.com/investors/annual-reports,http://mp-branding.com/investors/corporate-governance,http://mp-branding.com/investors/events-calendar,http://mallinckrodt.com/contact-us,http://dmpmandyou.com/investors,http://dmpmandyou.com/investors/presentation-documents,http://stopinfantilespasms.org/contact-us,http://stopinfantilespasms.org/investors,http://mallinckrodtbranding.com/investors/events-calendar,http://mallinckrodtbranding.com/investors/presentation-documents,http://mallinckrodtbranding.com/investors/supplemental-financial-information,http://stopinfantilespasm.org/investors,http://stopinfantilespasm.org/investors/annual-reports,http://stopinfantilespasm.org/investors/events-calendar,http://stopinfantilespasm.org/investors/presentation-documents,http://dmpmandyou.com/investors/events-calendar,http://mallinckrodtbranding.com/contact-us,http://dmpmandyou.com/investors/supplemental-financial-information,http://dmpmandyou.com/contact-us,http://stopinfantilespasm.com/contact-us,http://stopinfantilespasm.org/contact-us,http://mp-branding.com/contact-us,http://mnk.com/contact-us
hrhelpline@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",91,personal,13,{first}.{last},,,,,,,,http://hotel-rose.eu/blog/therakos.html,http://dmpmandyou.com/careers,http://stopinfantilespasm.org/careers,http://mp-branding.com/careers,http://stopinfantilespasms.org/careers,http://stopinfantilespasm.com/careers,http://stopinfantilespasm.net/careers,http://stopis.org/careers,http://mp-brand.com/careers,http://mallinckrodtbrand.com/careers,http://mallinckrodtbranding.com/careers,http://www2.mallinckrodt.com/careers,http://mallinckrodt.com/careers,,,,,,,,,,,,,,,,
board.directors@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",91,generic,13,{first}.{last},,,,,,,,http://dmpmandyou.com/contact-us,http://stopinfantilespasm.org/contact-us,http://stopinfantilespasms.org/contact-us,http://stopinfantilespasm.com/contact-us,http://stopinfantilespasm.net/contact-us,http://stopis.org/contact-us,http://mp-branding.com/contact-us,http://mallinckrodtbrand.com/contact-us,http://mp-brand.com/contact-us,http://mnk.com/contact-us,http://www2.mallinckrodt.com/contact-us,http://mallinckrodt.com/contact-us,http://mallinckrodtbranding.com/contact-us,,,,,,,,,,,,,,,,
pvgenerics@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",91,personal,20,{first}.{last},,,,,,,,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://dmpmandyou.com/products/generics/generics-contact,http://stopinfantilespasm.org/products/generics/generics-contact,http://mp-branding.com/products/generics/generics-contact,http://stopinfantilespasms.org/products/generics/generics-contact,http://stopinfantilespasm.com/products/generics/generics-contact,http://stopinfantilespasm.net/products/generics/generics-contact,http://stopis.org/products/generics/generics-contact,http://mp-brand.com/products/generics/generics-contact,http://mallinckrodtbranding.com/products/generics/generics-contact,http://mallinckrodt.com/products/generics/generics-contact,http://mallinckrodt.ca/fr/nous-contacter,,,,,,,,,
studyinfo@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",91,generic,12,{first}.{last},,,Support,,,,,http://dmpmandyou.com/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://stopinfantilespasm.org/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://stopinfantilespasms.org/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://stopinfantilespasm.com/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://stopinfantilespasm.net/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://stopis.org/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://mp-branding.com/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://mallinckrodtbrand.com/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://mp-brand.com/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://mallinckrodt.com/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://mallinckrodtbranding.com/research/medical-affairs/research-educational-grants/investigator-initiated-research,http://mallinckrodt.versaic.com/message/profile_inactive,,,,,,,,,,,,,,,,,
specialtybrandspm@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",91,personal,21,{first}.{last},,,,,,,,http://mallinckrodt.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mallinckrodt.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mp-branding.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mp-branding.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://dmpmandyou.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://dmpmandyou.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mallinckrodtbrand.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://dmpmandyou.com/products/brands/brands-contact,http://stopinfantilespasm.org/products/brands/brands-contact,http://mp-branding.com/products/brands/brands-contact,http://stopinfantilespasms.org/products/brands/brands-contact,http://stopinfantilespasm.com/products/brands/brands-contact,http://stopinfantilespasm.net/products/brands/brands-contact,http://stopis.org/products/brands/brands-contact,http://mallinckrodtbrand.com/products/brands/brands-contact,http://mallinckrodt.com/products/brands/brands-contact,http://mallinckrodtbranding.com/products/brands/brands-contact,,,,,,,,
medinfo@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",91,generic,30,{first}.{last},,,Support,,,,,http://mallinckrodt.com/globalassets/documents/corporate/bibliography/acthar-gel-repository-corticotropin-injection-reference-bibliography.pdf,http://mallinckrodt.com/globalassets/documents/corporate/bibliography/inomax_nitric_oxide_gas_inhalation_reference_bibliography_8_3_2020.pdf,http://mallinckrodt.com/globalassets/documents/corporate/bibliography/uvadex_methoxsalen_reference_bibliography_8_3_2020.pdf,http://mallinckrodt.com/globalassets/documents/corporate/mi-phone-numbers---global---august-2023.pdf,http://mallinckrodt.ca/fr/nous-contacter,http://felleskatalogen.no/ir/medisin/firmaer/therakos-658316,http://mp-branding.com/globalassets/documents/corporate/bibliography/acthar-gel-repository-corticotropin-injection-reference-bibliography.pdf,http://mp-branding.com/globalassets/documents/corporate/bibliography/inomax_nitric_oxide_gas_inhalation_reference_bibliography_8_3_2020.pdf,http://mp-branding.com/globalassets/documents/corporate/bibliography/uvadex_methoxsalen_reference_bibliography_8_3_2020.pdf,http://mp-branding.com/globalassets/documents/corporate/mnk_medical_information_contacts.pdf,http://therakos.fr/contact-us,http://therakos.fr/healthcare-professionals/customer-support,http://dmpmandyou.com/globalassets/documents/corporate/bibliography/acthar-gel-repository-corticotropin-injection-reference-bibliography.pdf,http://dmpmandyou.com/globalassets/documents/corporate/bibliography/inomax_nitric_oxide_gas_inhalation_reference_bibliography_8_3_2020.pdf,http://dmpmandyou.com/globalassets/documents/corporate/bibliography/uvadex_methoxsalen_reference_bibliography_8_3_2020.pdf,http://dmpmandyou.com/globalassets/documents/corporate/mnk_medical_information_contacts.pdf,http://felleskatalogen.no/d/medisin/firmaer/therakos-658316,http://stopinfantilespasms.org/globalassets/documents/corporate/bibliography/acthar-gel-repository-corticotropin-injection-reference-bibliography.pdf,http://stopinfantilespasms.org/globalassets/documents/corporate/bibliography/inomax_nitric_oxide_gas_inhalation_reference_bibliography_8_3_2020.pdf,http://stopinfantilespasms.org/globalassets/documents/corporate/bibliography/uvadex_methoxsalen_reference_bibliography_8_3_2020.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/bibliography/acthar-gel-repository-corticotropin-injection-reference-bibliography.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/bibliography/inomax_nitric_oxide_gas_inhalation_reference_bibliography_8_3_2020.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/bibliography/uvadex_methoxsalen_reference_bibliography_8_3_2020.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/mnk_medical_information_contacts.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/mnk_medical_information_contacts.pdf,http://nnpdf.org/research/mallinckrodt-pharmaceuticals,http://mallinckrodtbrand.com/globalassets/documents/corporate/bibliography/acthar-gel-repository-corticotropin-injection-reference-bibliography.pdf,http://mallinckrodtbrand.com/globalassets/documents/corporate/bibliography/inomax_nitric_oxide_gas_inhalation_reference_bibliography_8_3_2020.pdf,http://felleskatalogen.no/medisin/firmaer/therakos-658316,http://mallinckrodt.ca/contact-us
generics.apinvoices@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",90,generic,9,{first}.{last},,,,,,,,http://mallinckrodt.com/globalassets/documents/corporate/mnk----monitor-report-1.pdf,http://dmpmandyou.com/globalassets/documents/corporate/mnk----monitor-report-1.pdf,http://stopinfantilespasms.org/globalassets/documents/corporate/mnk----monitor-report-1.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/mnk----monitor-report-1.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/mnk----monitor-report-1.pdf,http://mallinckrodtbrand.com/globalassets/documents/corporate/mnk----monitor-report-1.pdf,http://mp-brand.com/globalassets/documents/corporate/mnk----monitor-report-1.pdf,http://mp-branding.com/globalassets/documents/corporate/mnk----monitor-report-1.pdf,http://stopinfantilespasm.com/globalassets/documents/corporate/mnk----monitor-report-1.pdf,,,,,,,,,,,,,,,,,,,,
globalcomplaints@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",90,generic,11,{first}.{last},,,Support,,,,,http://mallinckrodt.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mallinckrodt.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mp-branding.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mp-branding.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://dmpmandyou.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://dmpmandyou.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/2022-product-monitoring--contact-us-form-for-website.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,http://mallinckrodtbrand.com/globalassets/documents/corporate/2022-product-monitoring-contact-us-form-for-website-backup.pdf,,,,,,,,,,,,,,,,,,
compliance.dept@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",90,generic,30,{first}.{last},,,,,,,,http://www2.mallinckrodt.com/contact-us,http://mallinckrodt.com/corporate-responsibility/corporate-compliance,http://mp-branding.com/corporate-responsibility/corporate-compliance,http://mallinckrodt.com/contact-us,http://mallinckrodt.com/about/partnering/suppliers/conflict-minerals-policy,http://dmpmandyou.com/corporate-responsibility/corporate-compliance,http://mallinckrodtbranding.com/corporate-responsibility/corporate-compliance,http://mallinckrodtbrand.com/corporate-responsibility/corporate-compliance,http://stopinfantilespasm.net/about/partnering/suppliers/conflict-minerals-policy,http://dmpmandyou.com/about/partnering/suppliers/conflict-minerals-policy,http://dmpmandyou.com/contact-us,http://stopinfantilespasm.org/about/partnering/suppliers/conflict-minerals-policy,http://stopinfantilespasm.org/contact-us,http://stopinfantilespasm.org/corporate-responsibility/corporate-compliance,http://stopis.org/about/partnering/suppliers/conflict-minerals-policy,http://stopinfantilespasms.org/about/partnering/suppliers/conflict-minerals-policy,http://stopinfantilespasms.org/contact-us,http://stopinfantilespasm.com/about/partnering/suppliers/conflict-minerals-policy,http://stopinfantilespasm.com/contact-us,http://stopinfantilespasm.net/contact-us,http://stopinfantilespasms.org/corporate-responsibility/corporate-compliance,http://stopis.org/contact-us,http://mp-branding.com/about/partnering/suppliers/conflict-minerals-policy,http://mp-branding.com/contact-us,http://mallinckrodtbrand.com/about/partnering/suppliers/conflict-minerals-policy,http://mallinckrodtbrand.com/contact-us,http://mp-brand.com/contact-us,http://mnk.com/contact-us,http://mallinckrodtbranding.com/about/partnering/suppliers/conflict-minerals-policy,http://mallinckrodtbranding.com/contact-us
mnk.procurement@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",90,generic,13,{first}.{last},,,,,,,,http://dmpmandyou.com/contact-us,http://stopinfantilespasm.org/contact-us,http://stopinfantilespasms.org/contact-us,http://stopinfantilespasm.com/contact-us,http://stopinfantilespasm.net/contact-us,http://stopis.org/contact-us,http://mp-branding.com/contact-us,http://mallinckrodtbrand.com/contact-us,http://mp-brand.com/contact-us,http://mnk.com/contact-us,http://mallinckrodt.com/contact-us,http://www2.mallinckrodt.com/contact-us,http://mallinckrodtbranding.com/contact-us,,,,,,,,,,,,,,,,
critcare-globalcomplaints@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",90,personal,10,{first}.{last},,,,,,,,http://dmpmandyou.com/products/brands/brands-contact,http://stopinfantilespasm.org/products/brands/brands-contact,http://mp-branding.com/products/brands/brands-contact,http://stopinfantilespasms.org/products/brands/brands-contact,http://stopinfantilespasm.com/products/brands/brands-contact,http://stopinfantilespasm.net/products/brands/brands-contact,http://stopis.org/products/brands/brands-contact,http://mallinckrodtbrand.com/products/brands/brands-contact,http://mallinckrodt.com/products/brands/brands-contact,http://mallinckrodtbranding.com/products/brands/brands-contact,,,,,,,,,,,,,,,,,,,
compassionateuse@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",90,personal,9,{first}.{last},,,,,,,,http://dmpmandyou.com/corporate-responsibility/expanded-access-program-for-investigational-products,http://stopinfantilespasm.org/corporate-responsibility/expanded-access-program-for-investigational-products,http://mp-branding.com/corporate-responsibility/expanded-access-program-for-investigational-products,http://stopinfantilespasms.org/corporate-responsibility/expanded-access-program-for-investigational-products,http://stopis.org/corporate-responsibility/expanded-access-program-for-investigational-products,http://mallinckrodtbranding.com/corporate-responsibility/expanded-access-program-for-investigational-products,http://mallinckrodtbrand.com/corporate-responsibility/expanded-access-program-for-investigational-products,http://mallinckrodt.com/corporate-responsibility/expanded-access-program-for-investigational-products,http://mnk.com/corporate-responsibility/expanded-access-program-for-investigational-drugs,,,,,,,,,,,,,,,,,,,,
joyce.pearl@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",89,personal,1,{first}.{last},Joyce,Pearl,,,,,,http://esot.org/team/mallinckrodt-therakos-uk-ltd,,,,,,,,,,,,,,,,,,,,,,,,,,,,
khurram.jamil@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",89,personal,1,{first}.{last},Khurram,Jamil,,,,,,http://aapsopen.springeropen.com/counter/pdf/10.1186/s41120-022-00052-7.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
catherine.jackson@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",89,personal,1,{first}.{last},Catherine,Jackson,,,,,,http://nbna.org/files/cs_nbna_spring_2018_final_rev02.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
dale.wright@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",89,personal,1,{first}.{last},Dale,Wright,,,,,,http://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-020-03609-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,
kassie.harrold@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",88,personal,1,{first}.{last},Kassie,Harrold,,,,,,http://phrma.org/-/media/project/phrma/phrma-org/phrma-refresh/certifications/compliance-officers-03-09-2023.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sandra.greene@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",88,personal,1,{first}.{last},Sandra,Greene,,,,,,http://hhmr.org/post/current-research-on-uveitis,,,,,,,,,,,,,,,,,,,,,,,,,,,,
kim.brown@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",88,personal,1,{first}.{last},Kim,Brown,,,,,,http://vsronline.org/2022-exhibit-directory,,,,,,,,,,,,,,,,,,,,,,,,,,,,
eileen.mcclendon@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",88,personal,1,{first}.{last},Eileen,Mcclendon,,,,,,http://s-a-s.org/saint-louis,,,,,,,,,,,,,,,,,,,,,,,,,,,,
devicetechnicalservices@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",87,generic,9,{first}.{last},,,Support,,,,,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,,,,,,,,,,,,,,,,,,,,
scicommmwg@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",87,personal,6,{first}.{last},,,,,,,,http://dmpmandyou.com/research/medical-affairs/research-educational-grants/medical-writing,http://stopinfantilespasms.org/research/medical-affairs/research-educational-grants/medical-writing,http://mp-branding.com/research/medical-affairs/research-educational-grants/medical-writing,http://mallinckrodtbrand.com/research/medical-affairs/research-educational-grants/medical-writing,http://mallinckrodt.com/research/medical-affairs/research-educational-grants/medical-writing,http://mallinckrodtbranding.com/research/medical-affairs/research-educational-grants/medical-writing,,,,,,,,,,,,,,,,,,,,,,,
globalpv@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",87,personal,10,{first}.{last},,,,,,,,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://mallinckrodt.ca/fr/nous-contacter,,,,,,,,,,,,,,,,,,,
ecp.productsupport@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",86,generic,9,{first}.{last},,,Support,,,,,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,,,,,,,,,,,,,,,,,,,,
akio.shiranita@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",86,personal,9,{first}.{last},,,,,,,,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,,,,,,,,,,,,,,,,,,,,
safety-inotherapy@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",85,personal,9,{first}.{last},,,,,,,,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,,,,,,,,,,,,,,,,,,,,
kobe.safety@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",85,generic,9,{first}.{last},,,Legal,,,,,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodt.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://dmpmandyou.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mallinckrodtbranding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,http://stopinfantilespasm.org/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_contact.pdf,http://mp-branding.com/globalassets/documents/corporate/pharmcovigilance_sept_2022_old.pdf,,,,,,,,,,,,,,,,,,,,
critcaretks-tksinfo@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",84,generic,9,{first}.{last},,,Support,,,,,http://therakos.fr/media/0nun4jbr/10-24-sito-symposium-invitation_agenda.pdf,http://therakos.fr/media/1cbhnw3r/mp-5101-sidem-padova-ecp-flyer-v1.pdf,http://therakos.fr/media/dw0j1epc/informations-destin%c3%a9es-aux-patients_comprendre-la-ecp-therakos-5.pdf,http://therakos.fr/media/sa1b502a/tks-hcp-medicated-patient-brochure.pdf,http://therakos.fr/media/wn1kznng/informations-destin%c3%a9es-aux-patients_comprendre-la-ecp-therakos.pdf,http://therakos.eu/media/0eyfdg5u/10-24-sito-symposium-invitation_agenda-it-1.pdf,http://therakos.eu/media/4lmayncc/mp-5101-sidem-padova-ecp-flyer-v1.pdf,http://therakos.eu/media/sa1b502a/tks-hcp-medicated-patient-brochure.pdf,http://therakos.eu/media/v2mppm5w/mp-5133-sidem-pisa-ecp-flyer-v1.pdf,,,,,,,,,,,,,,,,,,,,
pharma.contracts@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",84,personal,4,{first}.{last},,,,,,,,http://mallinckrodt.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://dmpmandyou.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://mallinckrodtbranding.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://mp-branding.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,,,,,,,,,,,,,,,,,,,,,,,,,
edi.support@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",83,generic,4,{first}.{last},,,Support,,,,,http://mallinckrodt.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://dmpmandyou.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://mallinckrodtbranding.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://mp-branding.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,,,,,,,,,,,,,,,,,,,,,,,,,
specgxapics@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",83,personal,5,{first}.{last},,,,,,,,http://dmpmandyou.com/products/active-pharmaceutical-ingredients/contact-api,http://stopinfantilespasm.org/products/active-pharmaceutical-ingredients/contact-api,http://mallinckrodt.com/products/active-pharmaceutical-ingredients/contact-api,http://mp-branding.com/products/active-pharmaceutical-ingredients/contact-api,http://mallinckrodtbranding.com/products/active-pharmaceutical-ingredients/contact-api,,,,,,,,,,,,,,,,,,,,,,,,
critcaretks-accountsreceivableeu@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",82,generic,6,{first}.{last},,,,,,,,http://therakos.fr/contact-us,http://therakos.fr/healthcare-professionals/customer-support,http://therakos.eu/es/healthcare-professionals/customer-support,http://therakos.eu/es/contact-us,http://therakos.eu/contact-us,http://therakos.eu/healthcare-professionals/customer-support,,,,,,,,,,,,,,,,,,,,,,,
customerservice.emea.fr@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",82,generic,7,{first}.{last},,,Support,,,,,http://therakos.fr/contact-us,http://therakos.fr/healthcare-professionals/customer-support,http://therakos.eu/es/healthcare-professionals/customer-support,http://therakos.eu/es/contact-us,http://therakos.eu/covid-19,http://therakos.eu/contact-us,http://therakos.eu/healthcare-professionals/customer-support,,,,,,,,,,,,,,,,,,,,,,
genericsmedinfo@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",81,generic,4,{first}.{last},,,Support,,,,,http://mallinckrodt.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://dmpmandyou.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://mallinckrodtbranding.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,http://mp-branding.com/globalassets/documents/products/generic-products/v2b-mal-3485.sg-catinteractive_update_021123.pdf,,,,,,,,,,,,,,,,,,,,,,,,,
sheila.talafous@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",81,personal,5,{first}.{last},,,,,,,,http://parseghianfund.nd.edu/2020/07/16/message-from-mallinckrodt-concerning-adrabetadex-transition,http://parseghianfund.nd.edu/2019/10/08/letter-from-mallinckrodt-concerning-the-vts-301-trial-in-the-uk,http://npuk.org/study-vts301-study-resumption-in-france,http://npuk.org/mallinckrodt-official-statement-regarding-the-study-301-suspension,http://parseghianfund.nd.edu/2019/08/02/mallinckrodt-update-concerning-vts-270-trial-in-the-uk-and-france,,,,,,,,,,,,,,,,,,,,,,,,
josephine.stapnes@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",80,personal,6,{first}.{last},,,,,,,,http://therakos.fr/media/1sxd45je/09-30-sm-nordic-ctcl.pdf,http://therakos.fr/media/ihfimvlc/11-04-sm-nordic-ecp-invitation_agenda.pdf,http://therakos.fr/media/xxycodlc/11-03-nordic-operator-day-oslo-invitation_agenda.pdf,http://therakos.eu/media/1ieo1hia/mp-5250-nordic-ecp-invitation-flyer-v2-1.pdf,http://therakos.eu/media/ljjh2nvv/09-30-sm-nordic-ctcl.pdf,http://therakos.eu/media/yfrh10b1/11-04-sm-nordic-ecp-invitation_agenda.pdf,,,,,,,,,,,,,,,,,,,,,,,
medicalaffairseu@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",80,personal,5,{first}.{last},,,,,,,,http://therakos.eu/healthcare-professionals/research-opportunities-educational-grants/the-mallinckrodt-2022-advancing-ecp-immunomodulation-investigator-award-in-solid-organ-transplantation/eia-faqs,http://therakos.fr/healthcare-professionals/research-opportunities-educational-grants/the-mallinckrodt-2022-advancing-ecp-immunomodulation-investigator-award-in-solid-organ-transplantation/eia-faqs,http://therakos.eu/es/healthcare-professionals/research-opportunities-educational-grants/the-mallinckrodt-2022-advancing-ecp-immunomodulation-investigator-award-en-trasplante-de-organo-solido/eia-faqs,http://therakos.eu/healthcare-professionals/research-opportunities-educational-grants/the-mallinckrodt-2021-advancing-ecp-immunomodulation-investigator-award/eia-faqs,http://therakos.eu/es/healthcare-professionals/research-opportunities-educational-grants/the-mallinckrodt-2021-advancing-ecp-immunomodulation-investigator-award/eia-faqs,,,,,,,,,,,,,,,,,,,,,,,,
communications@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",79,generic,1,{first}.{last},,,,,,,,http://mpbranding.com/globalassets/downloads/brand-resources/mpbrandgdlns-version-6.0-2018-final.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
franni.oldroyd@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",79,personal,4,{first}.{last},,,,,,,,http://njsop.org/aws/njsop/pt/sd/calendar/284599/_parent/layout_details/false,http://njsop.org/aws/njsop/pt/sp/southjersey,http://njtbts.com/aws/njsop/pt/sd/calendar/284599/_parent/layout_details/false,http://njtbts.com/aws/njsop/pt/sp/southjersey,,,,,,,,,,,,,,,,,,,,,,,,,
mnkmediarelations@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",79,generic,3,{first}.{last},,,Writing & communication,,,,,http://judicial.elconfidencialdigital.com/articulo/ultima-hora/comunicado-mallinckrodt-anuncia-premio-investigador-2020-avances-inmunomodulacion-fec-1/20200831184324011756.html,http://pharmiweb.com/press-release/2020-08-31/mallinckrodt-announces-2020-investigator-award-to-further-advances-in-ecp-immunomodulation,http://judicial.elconfidencialdigital.com/articulo/ultima-hora/comunicado-mallinckrodt-anuncia-premio-investigador-2020-avances-inmunomodulacion-fec-1/20200831164324011756.html,,,,,,,,,,,,,,,,,,,,,,,,,,
non@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",79,generic,1,{first}.{last},,,,,,,,http://etc2.5ch.net/test/read.cgi/qa/1081942447,,,,,,,,,,,,,,,,,,,,,,,,,,,,
customerservice.emea.de@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",79,generic,5,{first}.{last},,,Support,,,,,http://therakos.eu/es/healthcare-professionals/customer-support,http://therakos.eu/es/contact-us,http://therakos.eu/covid-19,http://therakos.eu/contact-us,http://therakos.eu/healthcare-professionals/customer-support,,,,,,,,,,,,,,,,,,,,,,,,
mpbranding@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",79,personal,2,{first}.{last},,,,,,,,http://mpbranding.com/globalassets/downloads/brand-resources/mpbrandgdlns-version-6.0-2018-final.pdf,http://mpbranding.com/utility-pages/register,,,,,,,,,,,,,,,,,,,,,,,,,,,
junichi.yoshimura@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",78,personal,2,{first}.{last},,,,,,,,http://jp.prnasia.com/story/90525-3.shtml,http://prnewswire.com/es/comunicados-de-prensa/mallinckrodt-anuncia-la-aprobacion-del-reembolso-en-japon-del-sistema-de-fotoferesis-extracorporea-cellex-301764778.html,,,,,,,,,,,,,,,,,,,,,,,,,,,
sanitizer@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",78,personal,3,{first}.{last},,,,,,,,"http://the-reporter.net/stories/mallinckrodt-donates-sanitizer-to-otps-during-pandemic,72343",http://aatod.org/covid-19,http://aatod.org/home-2,,,,,,,,,,,,,,,,,,,,,,,,,,
customerservice.emea.it@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",78,generic,5,{first}.{last},,,Support,,,,,http://therakos.eu/es/healthcare-professionals/customer-support,http://therakos.eu/es/contact-us,http://therakos.eu/covid-19,http://therakos.eu/contact-us,http://therakos.eu/healthcare-professionals/customer-support,,,,,,,,,,,,,,,,,,,,,,,,
customerservice.emea.en@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",78,generic,5,{first}.{last},,,Support,,,,,http://therakos.eu/es/healthcare-professionals/customer-support,http://therakos.eu/es/contact-us,http://therakos.eu/covid-19,http://therakos.eu/contact-us,http://therakos.eu/healthcare-professionals/customer-support,,,,,,,,,,,,,,,,,,,,,,,,
ines.sa@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",78,generic,1,{first}.{last},,,,,,,,http://theupperroom.co.uk/therakos/hamburg/hamburg-2018.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ard.unsubscribe@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",78,generic,1,{first}.{last},,,Writing & communication,,,,,http://acthar.com/patient-stories,,,,,,,,,,,,,,,,,,,,,,,,,,,,
cquality@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",77,generic,1,{first}.{last},,,,,,,,http://pharmacentral.com/wp-content/uploads/2022/02/mallinckrodt-gmp-certificate.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
hobart.hr@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",77,generic,5,{first}.{last},,,HR,,,,,http://cdoworkforce.org/news/onsite-job-fair-wednesday-april-13-2022,http://cdoworkforce.org/news/mallinckrodt-walk-in-wednesdays,http://cdoworkforce.org/news/mallinckrodt-walk-in-wednesdays-now-hiring-in-hobart,http://cdoworkforce.org/news/open-houses,http://cdoworkforce.org/blog/categories/open-houses,,,,,,,,,,,,,,,,,,,,,,,,
supplier.inquiry@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",77,generic,2,{first}.{last},,,,,,,,http://financialreports.eu/news/releases/20230823en90554,http://restructuring.ra.kroll.com/mallinckrodt,,,,,,,,,,,,,,,,,,,,,,,,,,,
critcaretks-info@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",77,generic,5,{first}.{last},,,Support,,,,,http://therakos.eu/coe-courses/interactive-workshop-on-dermatological-diseases,http://therakos.eu/coe-courses/interactive-workshop-on-lung-transplant-rejection-sep,http://therakos.eu/coe-courses/therakos-cellex-photopheresis-system-practical-course-june,http://therakos.eu/coe-courses/therakos-cellex-photopheresis-system-practical-course-sep,http://therakos.eu/therakos-institute/centres-of-excellence,,,,,,,,,,,,,,,,,,,,,,,,
erstattung@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",77,personal,1,{first}.{last},,,,,,,,http://therakos.eu/es/healthcare-professionals/health-economics/funding-support,,,,,,,,,,,,,,,,,,,,,,,,,,,,
therakoshealtheconomics.eu@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",77,generic,2,{first}.{last},,,,,,,,http://therakos.eu/es/healthcare-professionals/health-economics/funding-support,http://therakos.eu/healthcare-professionals/health-economics/funding-support,,,,,,,,,,,,,,,,,,,,,,,,,,,
info@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",76,generic,2,{first}.{last},,,Support,,,,,http://therakos.fr/media/4juaulkm/tks-6th-nordic-meeting-highlights-report-reapproval-4.pdf,http://therakos.eu/media/jdch0tba/tks-6th-nordic-meeting-highlights-report-reapproval-4.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,
tina.rezakhani@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",76,personal,1,{first}.{last},,,,,,,,http://nbna.org/files/cs_nbna_spring_2018_final_rev02.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
derek.naten@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",76,personal,2,{first}.{last},,,,,,,,http://financialreports.eu/news/releases/20230823en90554,http://accesshub.pdc.wa.gov/node/50628,,,,,,,,,,,,,,,,,,,,,,,,,,,
critcare-canadiancustomerservice@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",76,generic,1,{first}.{last},,,Support,,,,,http://inomax.com/contact-us/international-contacts,,,,,,,,,,,,,,,,,,,,,,,,,,,,
scicommmeg@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",76,personal,1,{first}.{last},,,,,,,,http://mallinckrodt.versaic.com/message/profile_inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,
clinicaltrials@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",76,generic,6,{first}.{last},,,,,,,,http://clinicaltrials.gov/ct2/show/results/nct02953821,http://clinicaltrials.gov/ct2/show/results/nct00570349,http://clinicaltrials.gov/ct2/show/results/nct00850993,http://clinicaltrials.gov/ct2/show/results/nct01601236,http://clinicaltrials.gov/ct2/show/results/nct00737594,http://clinicaltrialsgps.com/search-clinical-trials/trial-73104,,,,,,,,,,,,,,,,,,,,,,,
sara.pirnstill@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",75,personal,2,{first}.{last},,,,,,,,http://universityresearchpark.org/resident-companies/name/stratatech-corporation,http://universityresearchpark.org/resident-companies/char/s,,,,,,,,,,,,,,,,,,,,,,,,,,,
customerservice.emea.es@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",75,generic,4,{first}.{last},,,Support,,,,,http://therakos.eu/es/healthcare-professionals/customer-support,http://therakos.eu/contact-us,http://therakos.eu/es/contact-us,http://therakos.eu/healthcare-professionals/customer-support,,,,,,,,,,,,,,,,,,,,,,,,,
therakosinstitute@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",75,personal,1,{first}.{last},,,,,,,,http://therakos.eu/bocconi-partnership,,,,,,,,,,,,,,,,,,,,,,,,,,,,
actharpatientsupport@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",75,generic,1,{first}.{last},,,Support,,,,,http://actharhcp.com/acthar-patient-support/supporting-patients-and-practices/email-preview.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
inoflojapan@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",75,personal,1,{first}.{last},,,,,,,,http://inomax.com/contact-us/international-contacts,,,,,,,,,,,,,,,,,,,,,,,,,,,,
kazuo.nishiyama@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",75,personal,4,{first}.{last},,,,,,,,http://prnewswire.com/es/comunicados-de-prensa/mallinckrodt-anuncia-la-aprobacion-del-reembolso-en-japon-del-sistema-de-fotoferesis-extracorporea-cellex-301764778.html,http://oncologytube.com/article/39768/mallinckrodt-receives-approval-in-japan-of-the-cellex%c2%ae-extracorporeal-photopheresis-system-for-treatment-of-chronic-graft-versus-host-disease,http://oncologytube.com/channel/cancer-news,http://jp.prnasia.com/story/54942-3.shtml,,,,,,,,,,,,,,,,,,,,,,,,,
clinicaltrails@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",74,generic,1,{first}.{last},,,,,,,,http://clinicaltrials.gov/ct2/show/nct03656692,,,,,,,,,,,,,,,,,,,,,,,,,,,,
hklyre@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",73,personal,1,{first}.{last},,,,,,,,http://belov.mirmk.ru/antispam,,,,,,,,,,,,,,,,,,,,,,,,,,,,
pope@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",72,generic,1,{first}.{last},,,,,,,,http://blog.oncode.info/stuff/spamtrap,,,,,,,,,,,,,,,,,,,,,,,,,,,,
tamar.hodges@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",69,personal,0,{first}.{last},Tamar,Hodges,Legal,Prosecuting Attorney,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jennifer.asay@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",68,personal,0,{first}.{last},Jennifer,Asay,Management,Senior Director,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
tom.porrecca@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",60,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
darren.colvin@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",17,personal,0,{first}.{last},Darren,Colvin,,"","","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
connie.wong@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",15,personal,0,{first}.{last},Connie,Wong,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
elizabeth.kulp@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",15,personal,0,{first}.{last},Elizabeth,Kulp,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
kornkanok.phutrakul@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",14,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
erpiyolu@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",13,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
chkaldmt@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",10,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
rqmfzhn@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",10,generic,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
wdlmmyser@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",10,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
therakoscustomercare@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",10,generic,0,{first}.{last},,,Support,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
conflict.minerals@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",10,generic,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
npcadvocacy@mnk.com,mnk.com,Mallinckrodt,US,MO,Webster Groves,63119,"",10,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
